-+ 0.00%
-+ 0.00%
-+ 0.00%
Innoscripta (XTRA:1INN) Stock Price Trails A Powerful Profit Engine
Share
Listen to the news

innoscripta walked into this earnings print with a stock that has slipped about 7% over the past week and about 15% over three months, despite trading on a P/E that sits below both peers and the wider European software group. The headline today is not the revenue dip in the quarter. It is the earnings machine behind the quieter top line. Trailing net income of €51.3m on €122.4m in revenue, a margin near 42%, reflects why sentiment is conflicted. The market is reacting to short term noise while the profit engine remains the core story.

Love innoscripta's strong profit engine but worried the market is still punishing the stock for short term revenue noise? Compare it with our 611 high quality undiscovered gems to see how other high margin companies with solid fundamentals are being valued.

Q2 2026 Earnings Summary

  • Revenue (Q2 2026 vs Q2 2025): €22.90m vs €18.52m (up about 23.6%)
  • Net Income (Q2 2026 vs Q2 2025): €6.27m vs €5.06m (up about 24.0%)
  • Basic EPS (Q2 2026 vs Q2 2025): €0.63 vs €0.51 (up about 24.6%)
  • Net Profit Margin (trailing 12 months to Q2 2026 vs prior year): 41.9% vs 39.5% (margin improved)

Prefer clear charts instead of scrolling through dense tables of earnings figures and margins? Get a full visual view of innoscripta’s financial picture, with a focus on its valuation profile, in the interactive company report for innoscripta.

XTRA:1INN Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
XTRA:1INN Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Innoscripta results keep the profit story intact

For investors leaning positive on innoscripta, the latest results broadly back the idea of a resilient profit engine. H1 2026 revenue moved from €44m to €63m while EBIT rose from €24.5m to €36.4m. Profit is growing faster than sales, which fits a software model with attractive operating leverage. Low churn below 2% and improved cash collection above 108% point to a sticky, paying customer base. Management’s decision to reaffirm guidance of €140m revenue and €80m EBIT for 2026 signals confidence in the underlying business, despite a temporary revenue drag from the platform migration.

Short term risks and market caution around innoscripta

The cautious view on innoscripta also has support in the recent numbers and commentary. Q2 revenue was held back by the platform migration, and management still needs to prove that submission volumes catch up in H2. International expansion into France, the U.K. and the U.S. is raising sales and marketing costs and is not expected to add much revenue in 2026. Price competition in France and higher salary levels abroad could pressure margins if growth slows. The share price is down about 15% over 90 days, which shows that investors are already pricing in some execution risk.

Compare whether innoscripta’s high margin profile and reaffirmed 2026 guidance line up with the recent €76.7 share price reaction, or if analysts see a different path ahead. See the consensus price target analysis for innoscripta

Take Control Of Your Next Move

If innoscripta’s high margin profile and reaffirmed 2026 targets have your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and identify a potential entry that fits your plan. Once you own the stock, use the Portfolio Command Center to cut through market noise and focus on the key updates that matter for your holdings. For longer term conviction building, tap into the Community to see how other investors are thinking about risks, catalysts and portfolio fit. This way you can review potential turning points early and stay a step ahead of the market with a clearer view of both opportunity and risk.

Seeking Alternatives Beyond Innoscripta?

Fresh stock ideas can move from quiet to flying once momentum builds and others catch on. Use these curated shortlists before the crowd and get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending